IRUBIS, a Munich-based biotech startup specializing in real-time bioprocess monitoring through mid-infrared spectroscopy, has successfully completed a pre-series A funding round. Leading the round was BioProcess360 Partners, accompanied by investors like High-Tech Grunderfonds (HTGF), Verve Ventures, Ventura BioMed Investors, and RoBet KG. The startup aims to use the funds to boost its innovative Monipa technology, which measures Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs) in biomanufacturing, enhancing Good Manufacturing Practices (GMP) readiness and expanding its application scope. IRUBIS’s technology aims to bring efficiency and quality to bioprocessing, and it is already generating significant industry traction. Founders Lorenz Sykora-Mirle, Alexander Geiler, and Anja Müller, along with stakeholders from BioProcess360, emphasize the crucial role of the investment in fulfilling IRUBIS’s potential in improving life-saving drug development processes.
Biotechnology, Venture Capital, Life Sciences,Germany, Switzerland
https://www.htgf.de/en/htgf-pre-series-a-irubis/